Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV type 1 strains

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1513-1523

  Férir, Geoffrey ^a   Huskens, Dana ^a   Palmer, Kenneth E ^b   Boudreaux, Daniel M ^c   Swanson, Michael D ^c   Markovitz, David M ^c   Balzarini, Jan ^a   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BANANA LECTIN; CARBOHYDRATE BINDING AGENT; GALANTHUS NIVALIS AGGLUTININ; GLYCAN; GLYCOPROTEIN GP 120; GRIFFITHSIN; HIPPEASTRUM HYBRID AGGLUTININ; MANNOSE; MICROVIRIN; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY B12; TENOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING COMPETITION; BINDING SITE; CARBOHYDRATE ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENTIATION; DRUG SPECIFICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PRIORITY JOURNAL; STEREOSPECIFICITY; VIRUS ENVELOPE; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CARBOHYDRATE METABOLISM; DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; PLANT LECTINS;

EID: 84868589152     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0026     Document Type: Article

References (52)

1. Leonard CK, Spellman MW, Riddle L, et al.: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265(18):10373-10382.
2. Scanlan CN, Offer J, Zitzmann N, et al.: Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 2007;446(7139):1038-1045.
3. Balzarini J: Targeting the glycans of glycoproteins: A novel paradigm for antiviral therapy. Nat Rev Microbiol 2007;5(8):583-597.
4. Balzarini J, Schols D, Neyts J, et al.: Alpha-(1-3)-and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomeg-alovirus infections in vitro. Antimicrob Agents Chemother 1991;35(3):410-416.
5. Swanson MD, Winter HC, Goldstein IJ, et al.: A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem 2010;285(12):8646-8655.
6. Emau P, Tian B, O'Keefe B R, et al.: Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV mi-crobicide. J Med Primatol 2007;36(4-5):244-253.
7. Mori T, O'Keefe BR, Sowder RC, 2nd, et al.: Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280(10):9345-9353.
8. Kouokam JC, Huskens D, Schols D, et al.: Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One 2011;6(8):e22635.
9. Huskens D, Férir G, Vermeire K, et al.: Microvirin, a novel {alpha}(1, 2)-mannose-specific lectin isolated from micro-cystis aeruginosa, has comparable anti-HIV-1 activity as cyanovirin-N, but a much higher safety profile. J Biol Chem 2010;285(32):24845-24854.
10. Buchacher A, Predl R, Strutzenberger K, et al.: Generation of human monoclonal antibodies against HIV-1 proteins; elec-trofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10(4):359-369.
11. Scanlan CN, Pantophlet R, Wormald MR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1/2 mannose residues on the outer face of gp120. J Virol 2002;76(14):7306-7321.
12. Agrawal-Gamse C, Luallen RJ, Liu B, et al.: Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol 2011;85(1):470-480.
13. Malcolm RK, Edwards KL, Kiser P, et al.: Advances in mi-crobicide vaginal rings. Antiviral Res 2010;88(Suppl 1):S30-3 9.
14. Brouwers J, Vermeire K, Grammen C, et al.: Early identification of availability issues for poorly water-soluble micro-bicide candidates in biorelevant media: A case study with saquinavir. Antiviral Res 2011;91(2):217-223.
15. Kiser PF, Mahalingam A, Fabian J, et al.: Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci 2012;101(5):1852-1864.
16. Nel AM, Coplan P, van de Wijgert JH, et al.: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009;23(12):1531-1538.
17. Nel AM, Coplan P, Smythe SC, et al.: Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010; 26(11):1181-1190.
18. Romano J, Variano B, Coplan P, et al.: Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009;25(5):483-488.
19. Campbell-Yesufu OT and Gandhi RT: Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011;52(6):780-787.
20. MacNeil A, Sarr AD, Sankale JL, et al.: Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007;81(10):5325-5330.
21. Marlink R, Kanki P, Thior I, et al.: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265(5178):1587-1590.
22. Schim van der Loeff MF, Jaffar S, Aveika AA, et al.: Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002;16(13):1775-1783.
23. Ntemgwa ML, d'Aquin Toni T, Brenner BG, et al.: Anti-retroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009;53(9):3611-3619.
24. O'Keefe BR, Vojdani F, Buffa V, et al.: Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 2009;106(15):6099-6104.
25. Huskens D, Van Laethem K, Vermeire K, et al.: Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 2007;360(2):294-304.
26. Pauwels R, Balzarini J, Baba M, et al.: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20(4):309-321.
27. Vermeire K, Princen K, Hatse S, et al.: CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004;18(16):2115-2125.
28. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drug or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
29. Doncel GF and Clark MR: Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res 2010;88(Suppl 1):S10-1 8.
30. Baeten JM, Benki S, Chohan V, et al.: Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007;21(13):1771-1777.
31. Herrera C, Cranage M, McGowan I, et al.: Colorectal mi-crobicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS 2011;25(16):1971-1979.
32. Gantlett KE, Weber JN, and Sattentau QJ: Synergistic inhibition of HIV-1 infection by combinations of soluble poly-anions with other potential microbicides. Antiviral Res 2007;75(3):188-197.
33. Ketas TJ, Holuigue S, Matthews K, et al.: Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology 2012;422(1):22-36.
34. Shen L, Peterson S, Sedaghat AR, et al.: Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008;14(7):762-766.
35. Ferguson NM, Fraser C, and Anderson RM: Viral dynamics and anti-viral pharmacodynamics: Rethinking in vitro measures of drug potency. Trends Pharmacol Sci 2001;22(2):97-100.
36. Balzarini J, Van Laethem K, Peumans WJ, et al.: Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 2006;80(17):8411-8421.
37. Huskens D, Vermeire K, Vandemeulebroucke E, et al.: Safety concerns for the potential use of cyanovirin-N as a micro-bicidal anti-HIV agent. Int J Biochem Cell Biol 2008;40(12):2802-2814.
38. Shahzad-ul-Hussan S, Gustchina E, Ghirlando R, et al.: Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1-2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem 2011;286(23):20788-20796.
39. Alexandre KB, Gray ES, Pantophlet R, et al.: Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol 2011;85(17):9039-9050.
40. Hoorelbeke B, Huskens D, Férir G, et al.: Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 2010; 54(8):3287-3301.
41. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral mi-crobicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-1174.
42. Andrei G, Lisco A, Vanpouille C, et al.: Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011;10(4):379-389.
43. Férir G, Vermeire K, Huskens D, et al.: Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Res 2011;90:200-204.
44. Férir G, Palmer KE, and Schols D: Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 2011;417(2):253-258.
45. Bertaux C, Daelemans D, Meertens L, et al.: Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by poly-anions. Virology 2007;366(1):40-50.
46. Meuleman P, Albecka A, Belouzard S, et al.: Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother 2011;55(11):5159-5167.
47. Alexandre KB, Gray ES, Mufhandu H, et al.: The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 2012;423(2):175-186.
48. Tsai CC, Emau P, Jiang Y, et al.: Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004;20(1):11-18.
49. Tsai CC, Emau P, Jiang Y, et al.: Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003;19(7):535-541.
50. Lagenaur LA, Sanders-Beer BE, Brichacek B, et al.: Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011;4(6):648-657.
51. Van Damme L, Ramjee G, Alary M, et al.: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360(9338):971-977.
52. Abdool Karim S, Richardson B, Ramjee G, et al.: Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011;25(7):957-966.